Tyra Biosciences (NASDAQ:TYRA) Now Covered by Analysts at UBS Group

UBS Group assumed coverage on shares of Tyra Biosciences (NASDAQ:TYRA) in a report issued on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $28.00 price objective on the stock.

TYRA has been the subject of several other reports. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Oppenheimer increased their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, HC Wainwright dropped their price objective on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Trading Down 0.7 %

TYRA opened at $15.95 on Tuesday. The stock has a market capitalization of $807.12 million, a P/E ratio of -9.91 and a beta of 1.04. Tyra Biosciences has a 12-month low of $11.32 and a 12-month high of $29.60. The stock has a 50-day moving average price of $15.48 and a 200-day moving average price of $19.24.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, equities research analysts predict that Tyra Biosciences will post -1.57 EPS for the current year.

Insider Activity at Tyra Biosciences

In other news, CFO Alan Fuhrman purchased 9,500 shares of the stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $16.00 per share, with a total value of $152,000.00. Following the acquisition, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at $205,584. This represents a 283.67 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Todd Harris sold 15,394 shares of the firm’s stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $25.85, for a total transaction of $397,934.90. Following the completion of the transaction, the chief executive officer now directly owns 1,418,647 shares in the company, valued at approximately $36,672,024.95. The trade was a 1.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 84,160 shares of company stock worth $1,827,047 over the last quarter. Corporate insiders own 15.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp raised its holdings in Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock worth $929,000 after purchasing an additional 14,352 shares during the period. Rhumbline Advisers increased its position in Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after buying an additional 2,574 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after buying an additional 145,346 shares in the last quarter. Ensign Peak Advisors Inc bought a new position in shares of Tyra Biosciences during the 2nd quarter valued at approximately $3,047,000. Finally, HighVista Strategies LLC purchased a new stake in Tyra Biosciences in the 2nd quarter worth approximately $257,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.